List of Artificial Intelligence Companies in Israel - 29

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

Biolojic Design makes developable, active human antibodies directed against functional epitopes, including targets for which existing technologies fail.

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

Biology is at a tipping point for implementing AI - thanks to rich data, tool availability, compute capacity, and measurable business impact. Our goal is to empower every scientist and biotech firm, making AI-powered insights a natural part of every workflow. From alt-protein foods to new biopharmaceuticals, bioraptor will make it easier, quicker and more cost-effective for scientists to discover, develop and scale processes that get much-needed food and pharma products into the hands of those who need them.

For the first time, researchers and companies can accelerate innovation with accessible, accurate, real-time, and reliable Brain Data™ and Brain Insights™.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Convergent R.N.R (CRNR) developed a transformational AI driven robotic radiation platform that was exclusively designed to significantly reduce non-therapeutic dose to adjacent critical structures, disrupting a stagnant radiation therapy/surgery equipment market. The uniquely converging low energy x-ray beam fulfils the un-met proton beam therapy promise, for a less toxic (to nearby organs) radiation solution, at a fraction of the cost, while reducing total cost of ownership by eliminating the need for a concrete bunker.

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

DermaDetect is an AI driven software which enables remote diagnosis and treatment of skin disorders. Based on the latest technology, the system helps health care providers grow the efficiency of their workflow, profitability of their clinic while significantly improving patient care. Based on intelligent software, the platform integrates easily with existing systems, is easy to use, accessible 24/7 and has an attractive pay-per usage pricing model.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world's first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

Enzymit is setting a new paradigm for bioproduction through the design and creation of novel enzymes that streamline production processes, reduce costs and promote sustainability. Through cell-free, synthetic biology bioproduction, we aim to make faster, simpler, and more cost-effective than fermentation-based methods, meeting the demands of a constantly evolving world. Established in 2020 by experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

Eybna is a technology company and a leading terpene manufacturer. Eybna's forward-thinking R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna's strong and profound partnership with academia and leading industry partners, allows the company to constantly integrate advanced research in the process of product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel, and a US office based in California.

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

HT BioImaging is a medical imaging company based in Tel Aviv, Israel, founded in 2015. The company specializes in innovative imaging technologies aimed at early cancer detection. Its main product is a patented medical imaging platform that uses Heat Diffusion Imaging (HDI) technology to create real-time images from heat diffusion in tissues. This platform is designed for immediate cancer detection at the point of care and in operating rooms. In addition to its primary focus on human healthcare, HT BioImaging has a subsidiary called HTVet, which applies its technology to the veterinary market. HTVet offers HT Vista, a non-invasive medical device that helps veterinarians rule out cancer in pets during clinical visits. The company serves hospitals and clinics, particularly in oncology and surgery, and is supported by a team of experts in various fields, including AI and thermodynamics.

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

At JaxBio, we are revolutionising the way cancer is diagnosed and managed by making cancer detection simpler, quicker, and more precise, and we're doing that through our innovative blood test technology. Our unique blood test offers advantages over traditional methods and traditional liquid biopsies. Based on its high sensitivity together with low cost and simplicity, we can deliver results faster with improved accuracy. By improving screening and early detection capabilities for cancer, healthcare providers and patients can now make better informed decisions sooner when time is of the essence. We use novel artificial intelligence (AI) algorithms to identify sets of biomarkers that are effective in detecting various types and subtypes of cancer at different stages. Our tests aren't just for initial diagnosis; they're also valuable tools for monitoring disease status and predicting how well a patient will respond to therapy. Our platform technology can also be used in a range of diseases, including various types of cancer, neurodegenerative diseases, and heart diseases. Connect with us to learn more.

MNDL Bio is a Synthetic Biology startup aiming to reduce cost and production time of food and biotech applications through advanced computational platforms that optimize gene expression. Proud winner of the "Coller Startup Competition" for Edition 2023.

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

Oxitone is a leading wearables and digital health company helping providers deliver continuous remote care for people with severe chronic and complex conditions and ensure the best clinical outcomes. MAXIMIZE VALUE AT LOW COST The top 5% of people with severe chronic conditions account for 50% of care spending. Practicing fragmented care doesn't deliver help in time. Oxitone generates continuous remote measurements of multiple physiological parameters and their derivatives, so any critical deviations could be flagged and notified in a timely manner. Oxitone continuous monitoring solution helps to maximize care for patients while significantly reduce cost. VitalsTone™ AI-POWERED ANALYTICS ENGINE At the core of Oxitone is the VitalsTone™ exceptionally accurate personalized data analytics engine integrated with the #1 in the market FDA/CE certified wrist medical monitor Oxitone 1000M. It passively collects and analyses multiple critical physiological parameters and their derivatives (hospital-grade) in real time and guides personalized therapeutic decision-making ULNAR BONE FlexSense™ CONTINUOUS MONITORING TECHNOLOGY Oxitone 1000M is the first FDA-cleared wrist medical monitor that works without a bulky fingertip probe. Oxitone's elastics sensors gently embrace wrist ulnar bone, do not affect local blood flow and provide superior accuracy, comfort and monitoring continuity. The technology was intensively validated through FDA clearance and numerous clinical applications. Oxitone is spotlighted on The New York Times, MobiHealthNews, MedCityNews, and Digital Health Global 100. Won awards from Cleveland Clinic, NODE.Health, Tech Tour, and Hello Tomorrow. Oxitone was a part of StartUp Health and TEDMED Hive 2014.

Pepticom is a unique Artificial Intelligence (AI) platform company with disruptive technology for peptide discovery. The platform is based on research carried out in the Hebrew University and extensively developed further by the company. Pepticom's disruptive technology allows for the discovery of quantity and quality innovative peptides and other molecules at a fraction of the time and cost of the traditional laboratory discovery methods. The peptide discovered can be used as drugs, in agriculture and animal well-being. Pepticom is engaged in various discovery projects such as ADAMA in the field of agriculture and with other big companies in the Pharmaceutical filed.

Utilizing a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data

Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

Here at Redefine Meat, we believe the world deserves better meat – a new kind of meat that's good for the environment, kinder to animals, and of course, delicious. With cutting-edge technology, we've created plant-based ‘New Meat' that has the same flavor, texture, and versatility as animal meat. We offer a wide range of products suitable for any type of cuisine and cooking style.

Ukko is improving the lives of millions that suffer from food allergies and disorders. We are using cutting edge technologies in immunology, computational biology, and plant science to develop a new approach. We have offices in Tel Aviv, Israel and Palo Alto, California.